AtriCure (ATRC) Q3 2026 earnings review
AtriCure raises its profit outlook, though catheter rivals shrink one unit
AtriCure's newer open-heart and pain-blocking tools sped up in the third quarter while its minimally invasive heart business kept shrinking. The maker of surgical heart devices and nerve-freezing probes grew worldwide sales 15% from a year ago to $154 million, beating its own call for a summer dip. Chief executive Michael Carrel raised the full-year profit outlook again as gross margin held at 77%.
| Worldwide revenue | $154.5M +15.0% from a year ago |
|---|---|
| US pain management sales | $28.1M +34.6% from a year ago |
| Gross margin | 77.3% +1.8 percentage points from a year ago |
| Full-year profit outlook | Raised cash profit target up $5.5M at the middle |
⚖️ Verdict: 🟢 Bullish
The story got better because US pain management broke out to 35% growth and gross margin held its record level despite planned factory additions. Those two drivers allowed the company to absorb a $4.5 million research milestone charge and still lift its full-year cash profit target. One caution: growth in heart-appendage clips slowed overseas, and minimally invasive ablation fell faster as cardiologists switched to rival catheter treatments.
The question now is whether the sharpfourth-quarter profit slowdown implied by the full-year plan is real factory cost pressure or another cautious target. By our math, the outlook leaves a 13.5% cash profit margin for the fourth quarter against 17.4% in the third. Fourth-quarter gross margin and appendage clip sales against new rivals will settle it.
🐂 Bull Case
US Pain and Open Heart Tools Accelerated
AtriCure's newer surgical tools are growing faster than they did in the first half of the year. Chief executive Michael Carrel said that "Adoption of our innovative technologies is driving strong growth and expanding profitability, while the rapid progress of our BoxX-NoAF clinical trial reinforces our confidence in the opportunities ahead." BoxX-NoAF is the company's clinical trial testing its tools to prevent irregular heartbeats in general heart surgery patients.
- US pain management sales: $28.1 million, up 34.6% from a year ago after four quarters between 27% and 30%
- US open-heart ablation sales: $43.0 million, up 20.8% from a year ago, up from 12.1% growth last quarter
- Total US revenue: $128.0 million, up 17.1% from a year ago
Surgeons bought more of the cryoSPHERE MAX probe, a device that freezes chest nerves to block post-surgery pain, and the EnCompass clamp, which burns heart tissue during open-heart operations to stop irregular rhythms. Because those two lines sped up at the same time, AtriCure grew revenue sequentially in the third quarter, when summer hospital schedules usually cause a dip.
What to watch: the end-of-year patient count for the 960-patient BoxX-NoAF trial in the fourth-quarter report. Completing enrollment on schedule this year would keep the medical device maker on track to apply for a much broader surgical label in 2027.
Gross Margin Held Record Highs as Overhead Shrank
Higher-priced US devices and tight control over day-to-day overhead are lifting profit much faster than sales. Gross margin, the share of sales left after the cost of making the products, rose 1.8 percentage points from a year ago to 77.3%. The surgical device maker attributed the gain to "favorable product and geographic mix" as high-margin US pain and open-heart devices grew fastest.
That 77.3% reading edged past last quarter's 77.2%, even though management had warned that a new factory would weigh on second-half margins. Meanwhile, selling, general and administrative expenses — sales reps and corporate overhead — grew 5.9% from a year ago, dropping 4.6 percentage points of revenue to 53.7%. Research and development rose 3.7 percentage points of revenue to 20.8%, but a $4.5 million milestone payment for acquired research accounted for 2.9 points of that jump.
What to watch: fourth-quarter gross margin and Adjusted EBITDA (operating cash profit excluding one-offs and stock pay). By our math, the full-year outlook points to Adjusted EBITDA growth slowing from 50.6% in Q3 to 7.5% in Q4, which will test whether new factory costs finally bite or the company set another cautious target.
🐻 Bear Case
Catheter Rivals Keep Shrinking Hybrid Surgery
AtriCure's Hybrid AF Therapy combines a surgeon's small-incision burn on the outside of the heart with a cardiologist's catheter treatment on the inside. Management has argued for two years that patients who fail new pulsed field ablation (PFA) catheter treatments — which use electrical pulses rather than heat or cold — will eventually return for this combined procedure.
Instead, the decline in US minimally invasive ablation got worse this quarter. Sales fell 27.5% from a year ago to $5.4 million, a steeper drop than the 23.1% decline in the second quarter, even though the year-ago comparison was much easier. The Ohio-based group blamed the drop on a "continued reduction in Hybrid procedures as physicians adopt PFA catheters to treat patients".
This cuts against the company's stabilization story because the rate of decline sped up just as comparisons eased. However, the shrinking unit now makes up only 4.7% of worldwide revenue, so fast growth in open-heart and pain tools easily covered the $2.0 million loss in quarterly sales.
What to watch: US minimally invasive ablation revenue in the fourth quarter against a $7.7 million year-ago base. Another drop above 20% would show that catheter substitution is still outrunning any returning patients.
Appendage Clip Growth Slowed as Rivals Entered
Appendage management — the AtriClip family of implants that close off a small pouch on the heart to prevent blood clots and strokes — is AtriCure's largest business at 40.5% of total sales. Larger medical device rivals Medtronic and Edwards Lifesciences have recently launched competing clips, and hospitals began testing those rival devices in the second half of 2026.
Worldwide appendage sales grew 12.3% from a year ago to $62.5 million, slowing from 14.4% growth in the second quarter. In the US, sales of the newer, smaller FLEX-Mini and PRO-Mini clips kept growth at 13.5%, down slightly from 14.4% last quarter. International appendage sales slowed much more sharply, rising 7.0% to $10.9 million after growing 14.5% in the second quarter, which dragged total international revenue growth down to 5.8%.
What to watch: fourth-quarter appendage growth in Europe and the US as AtriCure rolls out its Mini clips in Europe. A further slowdown below 10% worldwide would indicate that rival hospital trials are starting to take share or pressure prices.
Risks this quarter didn't answer
Three standing questions from prior quarters received no new numbers in the third-quarter earnings release because those details live in the quarterly filing or conference call.
- SentreHEART earnout lawsuit: former owners of an acquired product are suing for up to $260 million plus interest; the quarterly Form 10-Q legal footnote will show if the case moved.
- New pain probe saturation: cryoSPHERE MAX had already reached about 75% of US pain sales last quarter; call remarks will show how much conversion room remains or if new procedures drove the 34.6% jump.
- UK pain reimbursement: lost UK coverage previously cut British pain sales by three-quarters; the release only noted that international sales grew in all franchises.
💲 Other KPIs
Accounts receivable — money hospitals owe for delivered devices — fell $3.9 million from the second quarter, but still grew faster than sales from a year ago. Receivables rose 20.9% from a year ago against 15.0% revenue growth, marks a fifth straight quarter where uncollected bills outpaced top-line sales.
Physical buildings and equipment on the balance sheet jumped $24.2 million in the third quarter alone, up 70.4% from $39.1 million at the end of 2025. Over the same nine months, finance and operating lease liabilities nearly tripled from $11.5 million to $32.1 million as the new facility came onto the books.
Cash and cash equivalents rose $19.2 million in the third quarter to $187.0 million, while long-term debt stayed at $61.0 million. By our math, net cash before lease obligations reached $126.0 million, up from $106.8 million in the second quarter, even after paying a $4.5 million research milestone.
🔮 Guidance
Raised. AtriCure lifted the bottom of its full-year sales plan by $4 million, putting the middle of the range at $608 million, or 13.7% growth from 2025. By our math, that leaves $158.7 million for the fourth quarter, or 13.0% growth from a year ago against 15.0% in the third quarter. This is the second raise this year (+$1M at the middle in Q2, +$2M in Q3).
Raised. The middle of the full-year operating cash profit plan moved up $5.5 million to $92.5 million, or 49.8% growth for the year, following a $6 million raise last quarter. By our math, after generating $71.2 million in the first nine months, the plan leaves $21.3 million for Q4 — a 13.5% margin and 7.5% growth from a year ago, down from 50.6% growth in Q3.
Raised. The surgical group lifted its standard profit per share plan by $0.15 at the middle to $0.24, following a $0.07 raise in the second quarter. Because the company has already earned $0.27 per share in the first nine months, the middle of the full-year range implies a $0.03 per share loss in the fourth quarter by our math, pointing to further research milestone charges.
Raised. Profit per share excluding one-offs moved up $0.15 at the middle of the range to $0.43, after a $0.16 raise in the second quarter. With $0.36 already delivered through September, the middle of the plan leaves $0.07 per share for the fourth quarter by our math, compared with $0.18 in Q3 and $0.06 in the fourth quarter of 2025.
❓ Key Questions
What drove the 35% jump in US pain sales?
US pain management growth jumped from 27.8% in Q2 to 34.6% in Q3 even though the cryoSPHERE MAX probe had already reached 75% of US pain sales. Did existing chest accounts raise prices, or did newer breastbone and amputation procedures finally pass 10% of sales?
Why did international appendage clip growth halve in Q3?
International appendage management growth dropped from 14.5% in Q2 to 7.0% in Q3. Did hospitals in Europe pause orders ahead of the European launch of the FLEX-Mini and PRO-Mini clips, or are Medtronic and Edwards taking share outside the US?
Does the Q4 outlook include another research milestone charge?
AtriCure booked a $4.5 million acquired research charge in Q3, yet its nine-month profit of $0.27 per share still sits at the top of the raised $0.21–0.27 full-year outlook. How much additional milestone expense is built into the fourth-quarter plan?
Why did property and lease liabilities jump in Q3?
Property and equipment rose $24.2 million and lease liabilities rose $22.1 million in the third quarter. When does depreciation from this facility hit cost of sales, and does that explain why the outlook implies Adjusted EBITDA margin dropping from 17.4% to 13.5% in Q4?